BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

...made it relatively easy to attract outside LPs...
...with GSK investing $220 million (44%). Other LPs...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

...£15 million ($19.8 million). Novartis AG (NYSE:NVS; SIX:NOVN) and Cambridge Innovation Capital were among its LPs...
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...at Sofinnova Partners, told BioCentury. Its other LPs...
BioCentury | Oct 21, 2020
Deals

Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

...have a bad result and the money’s gone.”LPs...
BioCentury | Sep 30, 2020
Product Development

Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK

...of its Kurma Diagnostics 2 fund, which will invest in 15 early-stage European diagnostics companies. LPs...
BioCentury | Sep 25, 2020
Finance

With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

...oligonucleotide play Vico Therapeutics B.V. (see “Lava’s $83M Series C”; “Vico Revises Prosense Oligonucleotide Programs”). The firm’s LPs...
BioCentury | Sep 22, 2020
Finance

Medicxi adds firepower for maturing portfolio via first secondary fund

...by the firm’s predecessor organization, while offering liquidity and a reinvestment opportunity as options for LPs...
...the portfolio of the eight-year-old Index Ventures Life VI. The deal provides a return to LPs...
...Index Ventures prior to its life sciences team’s departure to form Medicxi in 2016. Those LPs...
BioCentury | Aug 14, 2020
Finance

OSI leverages foundational deal with Oxford to build its life sciences portfolio

...structure, any realized investments are recycled back into the fund, and rather than direct payments, LPs...
BioCentury | Jul 23, 2020
Finance

Amid measured expansion, Longwood raises $170M for fifth fund

...ArcherDx Inc. by Invitae (NYSE:NVTA), announced last month. Steinberg declined to name any of Longwood’s LPs...
BioCentury | Jul 10, 2020
Product Development

Atox looks towards 3Q20 NDA submission for necrotizing infection candidate following Phase III readout

Following its Phase III readout in necrotizing soft tissue infection, 17-year-old Atox is looking to bring lead product reltecimod to market, with plans to submit an NDA this quarter under the accelerated approval pathway. The...
Items per page:
1 - 10 of 681